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Abstract 
Introduction: The clinical heterogeneity and unpredictable clinical course of 
mitochondrial respiratory chain (MRC) disorders has hindered the development of 
effective therapeutic strategies for the treatment of these diseases. Treatment generally 
involves supportive therapy aimed at enhancing mitochondrial function as well as 
ameliorating increased reactive oxygen species (ROS) generation which is associated with 
MRC dysfunction. The purpose of this review is to focus on current biochemical strategies 
together with those that are being developed to treatment of MRC disorders. 
Areas covered: This review focusses on the biochemical strategies that have been developed 
to augment MRC function (increase electron transport and substrate availability in the MRC), 
scavenge ROS (antioxidant therapies) and modify mitochondrial biogenesis will be covered. 
The authors have comprehensively reviewed the literature to provide up to date information 
on these subjects. 
Expert opinion:  A consensus needs to be reached on the treatment of MRC disorders, 
and rather than the use of generic `antioxidant cocktails` case specific therapeutic 
strategies should be considered for the treatment patients. The inclusion of 
pharmacotherapies that target MRC function, cellular antioxidant status and 
mitochondrial biogenesis in the treatment regime of patients may be appropriate to 
ameliorate the defects in these parameters that contribute to disease pathophysiology. 
 
 
Article highlights  
 
 Mitochondrial respiratory chain (MRC) disorders are a complex group of diseases that 
have a heterogeneous clinical presentation and disease course creating formidable 
challenges for their effective treatment management. 
 The majority of therapeutic strategies available for the treatment of MRC disorders focus 
upon enhancing the activity of the MRC and restoring cellular antioxidant status. 
  Pharmaceutical agents that are capable of stimulating mitochondrial biogenesis and in 
some cases reversing MRC enzyme deficiencies have received a lot of attention over 
recent years with some of these compounds now entering clinical trials. 
 At present there is no consensus or unified approach to the treatment of MRC disorders 
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 Candidate therapies should be determined on a case specific basis.  Furthermore, it may be 
appropriate to include pharmaceutical agents that target MRC function, cellular antioxidant 
status and mitochondrial biogenesis in the treatment regime of patients in view of the 




The mitochondrial respiratory chain (MRC; Figure 1) consists of four enzyme complexes; complex I 
(NADH: ubiquinone reductase; EC 1.6.5.3); complex II (succinate: ubiquinone reductase; EC 1.3.5.1); 
complex III (ubiquinol: cytochrome c reductase; EC 1.10.2.2) ; complex IV (cytochrome c oxidase; EC 
1.9.3.1) and two mobile electron carriers, coenzyme Q10 (CoQ10) and cytochrome c and is located in 
the inner mitochondrial membrane [1,2]. The MRC together with complex V (ATP synthase; EC 
3.6.3.14; Figure 1) synthesizes ATP via the process of oxidative phosphorylation and consequently it 
is known as the oxidative phosphorylation |(OXPHOS) system [1]. Disorders of oxidative 
phosphorylation (disorders of the MRC and complex V) exhibit a phenotypic, genetic and 
biochemical heterogeneity which may reflect the dual genetic origin of the MRC and complex V 
which are encoded for by both nuclear DNA and mitochondrial DNA (mtDNA) [1]. Other factors such 
as heteroplasmy, the energy threshold of the tissue and the super-complex formation of the MRC 
may also contribute to this variability, although other unknown factors may also be involved [1,2]. 
Furthermore, mutations in genes encoding non-MRC components together with environmental 
factors may also be important contributory factors to these disorders [2]. In view of the paucity of 
research and limited clinical trials, there has been limited information available for the development 
of appropriate therapeutic strategies for the treatment of disorders of oxidative phosphorylation [3]. 
However, the recent establishment of national and international patient cohorts will provide a 
readily available patient resource for future clinical trials [4].  
Once a diagnosis has been accomplished, most patients with disorders of the MRC and complex V are 
offered symptomatic treatment [5], and in view of the multisystem presentation of these disorders, a 
broad range of medical specialties are involved in the management and treatment of these symptoms 
[6]. The majority of therapeutic strategies available for the treatment of MRC disorders focus upon 
enhancing the activity of the MRC and/or decreasing the level of oxidative stress (an imbalance 
between the production of free radicals, e.g. reactive oxygen species (ROS) and the body`s ability to 
neutralize these species) associated with these conditions [8]. In recent years, there has been 
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considerable interest in pharmaceutical treatments aimed at stimulating mitochondrial biogenesis as 
well as reversing the MRC enzyme defect underlying the disease [9].  
 This review will focus solely on the biochemical strategies used both currently and that are being 
developed for the treatment of MRC disorders, although some of these treatments also be applied 
to patients with complex V defects. 
 
 
2. Therapeutic strategies that target the mitochondria 
The therapeutic strategies that target the mitochondria can be divided into treatments that: 
1. Augment MRC function 
2. Scavenge ROS (antioxidant therapies) 
3. Modify mitochondrial biogenesis. 
Details and examples of these strategies are outlined in the following sections. 
 
2.1 Augmentation of MRC function 
One of the therapeutic strategies used for the treatment for MRC disorders is to try and increase the 
rate as well as the efficiency of electron flow in the MRC which would be expected to increase the rate 
of oxidative phosphorylation with the concomitant production of ATP.  The two current strategies 
used are:  
1. Enhancement of the efficiency of electron transport in the MRC. 
2. Increasing MRC substrate availability, in some cases by bypassing a defective enzyme complex [10].   
Once diagnosed patients with a MRC disorder, are generally treated with a `Mitochondrial Cocktail` 
which contains antioxidants and various cofactors and vitamins [11]. However, there is no overall 
consensus on the treatment of patients with these disorders. Commonly used agents which are 
administered orally as either a monotherapy or as a constituent of the `Mitochondrial Cocktail` 
include, coenzyme Q10 (CoQ10) and its analogue, idebenone and riboflavin (vitamin B2). 
 
2.2 CoQ10 
CoQ10 serves as an electron carrier in the MRC, transporting electrons derived from complex I and II 
to complex III and is therefore integral to the process of oxidative phosphorylation [12,13]. CoQ10 also 
serves to transfer electrons liberated from the -oxidation of fatty acids to complex III of the MRC [14] 
as well as being involved in DNA replication and repair through its role in pyrimidine synthesis [15]. 
More recently, CoQ10 has been shown to have a role in  hydrogen sulfide metabolism where it acts as 
an electron carrier in the reaction catalysed by sulfide: quinone oxidoreductase [16]. Therefore, in 
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addition to an impairment in oxidative phosphorylation a deficiency in CoQ10 status may also result in 
a perturbation of fatty acid b-oxidation, pyrimidine synthesis and hydrogen sulfide oxidation which all 
may contribute to disease pathophysiology. 
Primary CoQ10 deficiencies or defects in the CoQ10 biosynthetic pathway as the result of mutations in 
genes encoding for enzymes in the CoQ10 biosynthetic pathway and are unique amongst MRC 
disorders in that they are potentially treatable with high dose oral CoQ10 supplementation if diagnosed 
at an early stage of the disease [13]. Although, not all patients with primary CoQ10 deficiency appear 
to respond to oral CoQ10 supplementation, especially those with the neurological presentation of this 
disorder [13]. The reasons for this are uncertain but may include poor transference across the blood 
brain barrier (BBB) or irreversible structural damage prior to diagnosis and treatment [13].  Using the 
analysis of large-scale sequencing data it has been estimated that up to a maximum of 123,789 
individuals worldwide may suffer from primary CoQ10 deficiency with the majority of these patients 
as yet to be diagnosed [17]. 
In view of the possibility that treatment with CoQ10 may improve the efficiency of electron transport 
in patients with MRC disorders, CoQ10 supplementation is one of the most consistent therapeutic 
strategies used in the treatment of these diseases. Although   
there is a paucity of high level evidence supporting the use of CoQ10 in the treatment of patients with 
MRC disorders, a number of single and multiple case studies have reported evidence of increased 
strength, accelerated post exercise recovery and improvement in oxygen consumption in patients 
following CoQ10 supplementation [13,18]. The most consistent finding appears to be a decreased in 
plasma lactate level following CoQ10 supplementation [13,18].  
To date, there have only been a limited number of clinical trials that have assessed the efficacy of 
CoQ10 in the treatment of MRC disorders. Unfortunately, the results of these studies have been 
equivocal with no overall clinical benefit being  reported.  Although the low bioavailability and dosages 
of the CoQ10 formulations used in these studies together with the short durations of the trials may 
have contributed to the ambiguity of these results [19,20,21]. Typically, doses of CoQ10 in the range, 
5-50mg/kg/day are recommended for the treatment of patients with primary CoQ10 deficiency and 
soluble formulations of this agent are suggested rather than tablet forms in view of their higher 
bioavailability [13,18]. Furthermore, water soluble formulations of ubiquinol, the reduced form of 
CoQ10 have been reported to have better absorption and tissue and mitochondrial uptake than CoQ10 
and therefore, may prove to be a more effective therapeutic agent than CoQ10 [22]. 
 Unfortunately, at present no consensus exists on the appropriate dosages of CoQ10 to administer to 
patients with MRC dysfunction, although a dosage of at least 5mg/kg/day has been recommended 
[13,18]. Importantly, it has been suggested that patients with MRC disorders who have evidence of a 
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secondary CoQ10 deficiency (a CoQ10 deficiency associated with a mutation in a gene not involved in 
the CoQ10 biosynthetic pathway) may be more responsive to CoQ10 therapy and show evidence of 
clinical improvement following supplementation [23]. Moreover, this illustrates the important of 
determining the CoQ10 status of a patient prior to commencing CoQ10 supplementation [18].  It should 
also be noted that in addition to its ability to improve electron transport in the MRC, the therapeutic 
efficacy demonstrated by CoQ10 in the treatment of MRC disorders may also be the result of its 
antioxidant capacity [13,18]. 
 In view of the highly lipophilic nature of  CoQ10 which may limit its uptake into cellular membranes, 
alternative therapeutic strategies using structural analogues of 4-hydroxybenzoic acid (4-HB), the 
precursor of the benzoquinone nucleus of CoQ10 [24,25,26] have been suggested for the treatment of 
primary CoQ10 deficiencies . Studies in patient fibroblasts harbouring mutations in the CoQ10 
biosynthetic pathway gene, CoQ7 and mouse models with a genetic modification in the CoQ10 
biosynthetic gene, CoQ9 gene have indicated that the 4-HB analogue, 2,4‐dihydroxybenzoate has the 
potential to restore cellular CoQ10 biosynthesis, but this is dependent on the residual level of  the 
CoQ10 biosynthetic proteins [24,25]. In addition, the 4-HB and salicyclic analogue, -resorcyclic acid 
has been reported to show some therapeutic potential in the treatment of mitochondrial 
encephalopathy resulting from CoQ10 deficiency [26].  
  
2.3 Idebenone 
Idebenone is a short chain analogue of CoQ10 which is used to treat patients with MRC dysfunction 
being readily taken up by cells and in contrast to CoQ10, it appears to readily cross the blood brain 
barrier which is a semipermeable barrier that separates the brain from the blood stream [27].  
Idebenone in common with CoQ10 acts as an electron carrier in the MRC, however, in contrast to 
CoQ10, idebenone is thought to transfer electrons directly to complex III, thereby circumventing 
complex I [13]. Therefore, idebenone is not recommended as a treatment for primary CoQ10 
deficiencies and has been reported to cause  clinical deterioration  in patients with this condition and 
this is supported by the findings of the study  by Lopezet al. (2010) which showed that treatment  with 
this analogue was unable to restore the defective mitochondrial energy metabolism in fibroblasts 
from  CoQ10 deficient patients [28]. 
 
The mechanism by which idebenone is able to transfer electrons directly to MRC complex III, bypassing 
complex I is thought to result from its ability to act as a substrate for the cytosolic enzyme, 
NQO1(NAD(P)H dehydrogenase quinone 1) which is able to catalyse the transfer of electrons from 
NAD(P)H to idebenone [29]. Reduced idebenone then passes its electrons directly to MRC complex III 
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enhancing oxidative phosphorylation. Idebenone has been reported to be an effective treatment for 
the MRC disorder, Leber hereditary optic neuropathy (LHON) which is associated with an MRC 
complex I deficiency [13]. Idebenone treatment has been reported to prevent the loss and aid the 
recovery of visual acuity in LHON in addition to preventing the loss of colour vision [30,31]. Idebenone 
has also been reported to improve cerebral oxidative metabolism in MELAS patients [32]. In addition 
to acting as an electron carrier in the MRC, idebenone can also act an antioxidant which may also 
contribute to its clinical efficacy in the treatment of MRC disorders [10].  
 
2.4 Riboflavin  
Riboflavin or vitamin B2 acts as a precursor of FMN (Flavin mononucleotide) and FAD (flavin adenine 
dinucleotide) which are prosthetic groups for MRC complex I and II, respectively [33]. Riboflavin 
obtained from the diet enters the mitochondria from the cytosol by means of specific transporters 
and is then converted into either FMN and FAD [33]. Therefore, riboflavin transporters are essential 
for the maintenance of mitochondrial riboflavin homeostasis which if impaired can result in MRC 
dysfunction with a consequent impairment of oxidative phosphorylation [33]. This is illustrated in 
cases of Brown Vialetto Van Laere disease which is associated with riboflavin transporter detects 
and a concomitant impairment in the activities MRC complex I and II in patient fibroblasts (skin 
cells) [34]. Patients with this riboflavin transporter defect have been reported to show clinical 
improvement following high dose riboflavin therapy [35].  Furthermore, patients with mutations 
in the ACAD9, the FADH2 dependent MRC complex I assembly factor have also been reported to show 
clinical improvement following treatment with riboflavin [36]. Commensurate with this clinical 
improve, an increased in MRC complex I activity was also reported in fibroblasts from patients with 
this condition following supplementation with riboflavin [37]. It has been suggested that the increase 
in the intra-mitochondrial FAD concentration following riboflavin supplementation may improve the 
folding capacity of mutant flavoprotein assembly factors [38]. 
 The biochemical efficacy of riboflavin therapy for MRC disorders not associated with riboflavin 
transporter defects or mutations in riboflavin dependent proteins is thought to result from the ability 
of riboflavin to maximize residual MRC complex I and II activities or enhance the assembly of the 
defective enzyme complexes [39].  
3.  Antioxidant therapies 
Mitochondria are major sites of ROS generation within the cell and under normal circumstances, the 
level of cellular ROS is tightly controlled by antioxidants and antioxidant enzyme systems having a 
physiologically important role in cell signaling [13,40]. However, in cases of MRC dysfunction, electron 
leakage from the chain can cause increased ROS production which can eventually overwhelm cellular 
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antioxidant defenses resulting in oxidative stress [13,41]. Under these conditions, oxidative damage 
can occur to the MRC enzyme complexes, mtDNA and mitochondrial membrane phospholipids, such 
as cardiolipin [13,41]. This can result in further damage to the MRC, increased ROS generation and 
extramitochondrial oxidative damage which can contribute to cellular and consequently organ 
morbidity [18,41,42].  In view of the detrimental effects of oxidative stress, therapeutic strategies 
targeted at replenishing cellular antioxidant status have shown some benefit in the treatment of 
patients with MRC disorders [12,13, 41]. Apart from CoQ10 and idebenone which were discussed in 
the previous sections of this chapter, other antioxidants can be administered to patients with MRC 
disorders and some notable ones will  discussed in the subsequent two sections. 
 
3.1 EPI-743 
 The tripeptide, reduced glutathione (GSH) serves a major cellular antioxidant being present in high 
concentrations with the mitochondrion [43]. Although GSH can serve as an antioxidant in its own right, 
it also serves as a cofactor for the enzyme, glutathione peroxidase which reduces lipid peroxides and 
hydrogen peroxide to water [44]. Evidence of decreased GSH levels have been reported in both in 
skeletal muscle [43] and white blood cells [45] of patients with MRC disorders. For this reason, there 
has been a lot of interest in developing therapeutic strategies to replenish cellular GSH status in 
patients with MRC disorders. Amongst the compounds which have been studied, the synthetic 
quinone, EPI-743 has shown particular promise [45]. Although the precise mechanism of action of EPI-
743 has yet to be fully elucidated, it is thought to replenish cellular GSH status by its ability to transfer 
electrons from NOQ1 [29] to the enzyme, glutathione reductase [46]. In children with the 
encephalopathic mitochondrial disease, Leigh syndrome, EPI-743 treatment was reported to cause a 
reversal of disease progression [47]. Interestingly, clinical improvement was accompanied by a 
significant increase in the GSH status of patient lymphocytes following EPI-743 treatment [47]. 
 
3.2 Modify mitochondrial biogenesis 
The Stimulation of mitochondrial biogenesis has received a lot of attention over recent years on the 
premise that as MRC disorders are associated with an impairment in oxidative phosphorylation, the 
ability to increase the mitochondrial content of the cell  may therefore compensate for the deficit in 
cellular energy generation. Evidence of increased mitochondrial biogenesis has been reported in 
patients with MRC disorders and is thought to represent an adaptive response to the perturbation in 
cellular oxidative phosphorylation [9].  
Mitochondrial biogenesis is under strict regulatory control with the transcriptional co-activator 
peroxisome proliferator activated receptor  co-activator-1PGC-1) coordinating the activation 
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of a host of transcription factors. These include the nuclear respiratory factors (NRF1+2) and the 
hormone receptors, PPARs (peroxisome proliferator activated receptor; nuclear hormone receptors) 
which control the expression of a number of genes (nuclear and mtDNA) encoding components of the 
MRC as well as proteins involved in their assembly [48.49] (Figure 2). Consequently, the up-regulation 
of PGC-1signaling could promote an increase in mitochondrial biogenesis and consequently, the 
number of mitochondria within the cell.  On a cautionary note, PGC-1 stimulates the biogenesis of 
all mitochondria within the cell whether functional or dysfunctional and therefore, it is uncertain as 
yet whether this therapeutic approach will ultimately prove beneficial to all patients with MRC 
disorders, and this requires further study.   
 PGC-1is activated by either deacetylation (carried out by sirtuin 1; Sirt1, Figure 2), phosphorylation 
(carried out by AMP-activated protein kinase; AMPK, Figure 1) or by PPAR  which up-regulates its 
gene expression (Figure 2) [51,52].  Pharmaceutical strategies which stimulate these different 
activation mechanisms have the potential to promote mitochondrial biogenesis and improve residual 
MRC function. 
 
3.3 PPAR  activators 
Bezafibrate which is commonly used in the treatment of lipid disorders is a pan-agonist activating all 
three of PPAR isoforms (,  and )[52]. However, only activation of the PPAR  isoform has only 
been associated with increased PGC-1  gene expression in skeletal muscle [51] (Figure 2). Studies in 
patient fibroblasts [53] and animal models of MRC disease [54] have reported evidence of an 
improvement in MRC function and increased mitochondrial biogenesis following bezafibrate 
treatment. However, in some mouse models of MRC complex IV deficiency, bezafibrate was not found 
to be effective in ameliorating MRC dysfunction [55,56].  
In vitro studies have indicated that the decanoic acid component of MCT ketogenic diet has the 
potential to induce mitochondrial biogenesis and also increase MRC function via its ability to act as a 
PPAR- agonist [57].  Decanoic acid treatment of fibroblasts from MRC complex I deficient patients 
was found to significantly increase the level of mitochondrial enrichment of the cell, although no 
improvement in complex I activity was noted [58]. Studies in animal models [59,60] and case studies 
of MRC disease patients  [61,62]  have reported beneficial effects such as improvement in MRC 
function,  increased cellular antioxidant status and amelioration of clinical symptoms following 
treatment with  the various forms of the  ketogenic diet.  
 
3.4 SIRT1 activators 
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Another promising therapeutic strategy to activate PGC-1 is by increasing the cellular pool of NAD+ 
and thereby increasing the activity of  the NAD+, dependent deacetylase, SIRT1 [63]. SIRT1 then 
deacetylates and consequently activates PGC-1 initiating mitochondrial biogenesis (Fig 2) [50]. 
Strategies to increase the cellular pool of NAD+ include supplementing with nicotinamide riboside [63] 
or pharmaceutical inhibition of the NAD+ consuming enzyme, poly ADP polymerase 1 (PARP) [64]. 
Nicotinamide riboside treatment has been reported to boost cellular levels of NAD+, induce 
mitochondrial biogenesis and ameliorate clinical symptoms in mouse models of mitochondrial disease 
[9,11,49]. Although, nicotinamide riboside treatment was not found to produce any beneficial 
therapeutic effect in a mouse model of MRC complex III deficiency, possibly as a consequence of the 
underlying starvation-like metabolic state of the mice [65]. 
 
3.5 AMPK activation 
 The AMP (adenosine monophosphate) analogue, 5-Aminoimidazole-4-carboxamide ribonucleotide 
(AICAR) has been reported to promote mitochondrial biogenesis by its ability to activate AMPK activity 
and stimulate the PGC-1 signaling cascade [66]. Studies in MRC complex I deficient patient 
fibroblasts have reported an increase in mitochondrial biogenesis and ATP production following 
treatment with AICAR [67]. In addition, AICAR treatment was also found to reduce the level of cellular 
oxidative stress in the fibroblasts [67]. Furthermore, AICAR treatment in mouse models of MRC 
complex IV deficiency was found to increase in complex IV activity in addition to improving exercise 
endurance [55]. However, due to its poor availability, short half and association with increased blood 
lactate and urate levels, the suitability of AICAR for use in patients with MRC disorders is questionable 
[9].  
 
4. Other treatments 
In mtDNA depletion syndrome resulting from a deficiency in the enzyme, thymidine kinase 2 (TK2), 
supplementation with deoxynucleotides, deoxycytidine monophosphate and deoxythymidine 
monophosphate  has shown some promise in the treatment of a mouse model of this disorder with a 
delay in disease onset and increased life span being reported [68]. Furthermore, a recent open‐label 
study has indicated the beneficial therapeutic effects of deoxynucleoside monophosphate and 
deoxynucleoside therapies in the treatment of TK2 deficiency in  both children and adult patients [69].  
The antiobiotic compound, rapamycin has emerged as potential therapeutic candidate for the 
treatment of MRC disorders being reported to ameliorate the clinical and biochemical phenotypes of 
cell and mouse models of mitochondrial disease [70,71,72,73,74,75,76].  Cells and animals harbouring 
a complex I deficiency appear to particularly benefit from rapamycin treatment possibly as a 
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consequence of the antiobiotic`s ability to increase cellular energy status to some degree 
[70,71,72,73].    Rapamycin is able to inhibit the kinase function of the cytosolic serine/threonine 
kinase, mTOR1 which is a major cellular metabolic regulator, controlling the transition between 
anabolic and catabolic states as well as stimulating the de nova synthesis of nucleotides, lipids and 
proteins and inhibiting autophagy [77]. However, the involvement of mTOR1 in mitochondrial disease 
and mechanism of action of rapamycin in the treatment of these disorders has yet to be completely 
elucidated [76].  Interestingly, a recent study by Barriocanal-Casado et al (2019)  [78] which reported 
no therapeutic benefit following the treatment of a mouse model of CoQ10 deficiency with rapamycin 
has indicated that rapamycin therapy may not be a suitable treatment for all mitochondrial disease 
patients and that candidate therapies should be determined on a case specific basis.   
 
5. Conclusion 
The pathophysiology of mitochondrial disease is notoriously complex and unpredictable creating 
formidable challenges for its effective treatment management.  Following symptomatic treatment, 
therapeutic strategies generally focus upon enhancing MRC function and cellular energy generation 
as well as ameliorating oxidative stress. However, no consensus or unified approach exists at present 
to utilize these strategies effectively in the treatment of this disparate disease.  This may in part be 
attributable to the paucity of data available from clinical studies assessing therapeutic agents together 
with the heterogeneity of the MRC disease patient population.  Together with the use of 
`Mitochondrial Cocktails` containing  MRC cofactors and antioxidants, the addition of agents to 
enhance mitochondrial biogenesis may also be beneficial to patients with MRC disorders, although 
these strategies should be investigated in cell and animals of the disease before being translated to 
human studies.   
 
6. Expert opinion 
Although the therapeutic strategies to augment MRC function discussed in this review are currently 
used as part of the treatment regime of patients, other agents, especially those that have been 
reported to elicit mitochondrial biogenesis are only now beginning to be translated from animal 
studies into clinical trials in human subjects. Therefore, it may be sometime before patients are afford 
the potential beneficial effects of these pharmacotherapies. In view of the multiplicity of factors that  
may contribute to the pathophysiology of  MRC disorders, therapeutic strategies encompassing agents  
that target MRC function, cellular antioxidant status and mitochondrial biogenesis may be more 
appropriate than the `Mitochondrial Cocktails`  that are used to treat patients at present [11].  
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Furthermore, in view of the heterogeneous nature of MRC disorders, the instigation of specific patient 
based candidate therapies may be judicious for the treatment of these diseases [78].   
Currently, there are two major challenges that impact on the treatment of MRC patients. Firstly, the 
lack of a consensus or a unified approach to the treatment of MRC disorders. Although the 
establishment of national and international patient cohorts will provide a resource for the assessment 
of therapeutic strategies, at present, there is no international body that offers a platform for clinicians 
and scientists to debate the benefits and disadvantages of therapeutic regimes [4]. Secondly, the lack 
of reliable validated biomarkers or surrogates available for evaluating mitochondrial function in 
patients has hampered the ability to assess the clinical utility of candidate therapies [79] 
 At present, there is some uncertainties as to what will constitute the appropriate therapeutic 
strategies for the treatment of MRC disorders and regimes encompassing a multiplicity of 
pharmacotherapies to target MRC function, cellular antioxidant status and mitochondrial biogenesis 
may be the most appropriate.  Unfortunately, the use of combined pharmacotherapies raises the 
possibility of adverse drug interactions resulting in cellular toxicity and exacerbating patient morbidity 
[80].   Therefore, the use of single compounds that have the potential to target both MRC dysfunction 
as well as oxidative stress may be appropriate candidate therapies to treat patients with MRC 
disorders. Phytochemicals such as curcumin, resveratrol and quercetin appear to fulfill these criteria 
as demonstrated by in vitro cell culture and in vivo animals studies in addition to their ability to cross 
the BBB and enter the CNS [81,82,83].  Interestingly, a phase III clinical trial (Phase III clinical trial 
involves testing a drug on patients to assess its clinical efficacy and safety) has recently been 
completed in Thailand in which 70 patients with LHON were treated with curcumin 
(www.clinicaltrials.gov, NCT00528151), although the results of this study have yet to be reported. The 
author is unaware of any clinical studies that have assessed the efficacy of resveratrol treatment in 
primary MRC mitochondrial disease,  although an open-label clinical trial (a clinical trial in which 
patients and investigators know which agent the patients are receiving)  in Friedrich`s ataxia patients 
has reported improvement in neurological function, evidence of decreased oxidative, with  no serious 
adverse side effects being recorded [83]. Although quercetin  supplementation has been reported to 
reduce markers of oxidative stress and inflammation in healthy volunteers, no human studies have so 
far evaluated the effect of this  flavonoid  on the treatment of MRC dysfunction [85]. Although the 
reported low bioavailability of quercetin has limited its therapeutic potential, the construction of 
various quercetin-involved nanoparticles may be commensurate with its use as a future candidate 
therapy for the treatment of MRC disorders [86]. Indeed, the pharmacological manipulation of both 
resveratrol and curcumin may also be a consideration to enhance their bioavailability and therapeutic 
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potential. However, evidence of cellular toxicity would be required before translation into human 
studies with these modified phytochemicals. 
It is difficult to speculate how the treatment of MRC disorders will evolve in the future, although on a 
biochemical level, patient specific candidate therapies may have gained momentum and treatment 
regimes may encompass a variety of agents to target the specific aberrant parameter, be it energy 
metabolism or oxidative stress. However, together with biochemical agents, gene therapy and stem 
cell techniques may also be required to elicit some beneficial effects to patients. Importantly, until 
reliable biomarkers of MRC disorders become available, the potential therapeutic benefit of treatment 
strategies for these diseases may be underestimated.  
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